Clinical DevelopmentLast reviewed April 2026

Patient Narrative(Patient Narrative)

A structured clinical narrative describing the adverse event experience of an individual trial subject, required in clinical study reports.

Usage Examples

The pivotal Phase 3 CSR included 342 patient narratives covering all SAEs and AEs of special interest.
Narrative generation was automated from ADaM datasets with medical review of each draft.
Module 2.7.4 summarized the narrative set with cross-reference to the full CSR narratives.

What is Patient Narrative?

A patient narrative is a structured clinical narrative describing the experience of an individual subject in a clinical trial, focusing on safety events that required narrative documentation per ICH E3. Narratives are required for deaths, other serious adverse events, and adverse events of special interest as defined in the study protocol. Each narrative is typically 1-2 pages and covers demographics, medical history, study treatment, the event of interest, concomitant medications, outcome, and causality assessment.

For a typical Phase 3 pivotal study, patient narratives may number 300-500 individual cases, each requiring consistent structure, accurate event attribution, and careful language that neither over- nor under-states the clinical significance. Automated narrative generation from SDTM and ADaM datasets is now common; generated drafts are reviewed and edited by medical writers to add clinical judgment and contextualization.

Narratives appear in the Clinical Study Report (Module 5.3.5 of the CTD) as part of the safety evaluation. They also feed into Module 2.7.4 (Summary of Clinical Safety) and inform the benefit-risk assessment. Poorly written or inconsistent narratives are a common source of reviewer questions during regulatory review.

Regulatory Context

This term appears most often in clinical development workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside ICH E3, ICH E2A, ICH E6.

FDAEMAPMDA

When This Matters

The pivotal Phase 3 CSR included 342 patient narratives covering all SAEs and AEs of special interest.
Narrative generation was automated from ADaM datasets with medical review of each draft.
Module 2.7.4 summarized the narrative set with cross-reference to the full CSR narratives.

Common Mistakes

Applying one-region clinical assumptions to global submission strategies.
Missing protocol-to-regulation traceability for pivotal studies.
Underestimating how regional guidance updates impact trial documentation.

Related Regulations

ICH E3ICH E2AICH E6

Frequently Asked Questions

Per ICH E3: for all deaths, all serious adverse events, and all adverse events of special interest (protocol-defined). Some sponsors expand to include all discontinuations due to AE, pregnancies, and significant protocol deviations. The specific scope is agreed with regulators and documented in the Statistical Analysis Plan and CSR plan.

Yes. Given structured clinical data (SDTM and ADaM datasets), narratives can be auto-generated following a sponsor-defined template. Generation fills in subject demographics, event details, concomitant medications, and dates. Medical writers review, add clinical judgment, and edit where automated generation falls short.

Full narratives live in Module 5.3.5 (Clinical Study Reports) of the CTD, typically as a CSR appendix. Summary narrative themes feed into Module 2.7.4 (Summary of Clinical Safety) and the Integrated Safety Summary. Individual narratives may also be cited in deficiency responses when reviewers question specific cases.